RxDoctor Payments Data

Hylton Mayer, MD

Ophthalmology · Chevy Chase, MDNPI 1174568695

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 47.8% of the total. Reporting peaked in 2019 at $26,821 and has fallen 97.7% since, to $612 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,981in general payments, 2019–2025

Across 235 payments — averaging $221.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$25K
  • AbbVie$15K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
  • NEW World Medical,inc.$3K
  • Kala Pharmaceuticals, Inc.$1K
  • Alcon$777
  • plus $2K from 16 others
$96,849in research payments, 2019–2025

Across 73 payments — averaging $1326.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$91K
  • AbbVie$6K

What the payments were for

  • Consulting fees$13,61026%
  • Speaking & faculty fees$28,28554%
  • Travel & lodging$2,8996%
  • Food & beverage$7,15314%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,981 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$575,905
Medicare patients
828
Services billed
3,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost76$48,705
XiidraLifitegrast28$35,075
RhopressaNetarsudil Mesylate35$21,598
CombiganBrimonidine Tartrate/Timolol52$19,401
Brinzolamide62$13,487
VyzultaLatanoprostene Bunod17$11,513
SimbrinzaBrinzolamide/Brimonidine Tart25$9,987
MieboPerfluorohexyloctane/Pf11$9,536
Alphagan PBrimonidine Tartrate26$9,464
Brimonidine Tartrate57$8,188
Travatan ZTravoprost13$7,438
Travoprost37$6,877
Timolol MaleateTimolol Maleate/Pf19$6,390
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$4,316
Prednisolone Acetate70$4,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$14,726$77,571154 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$229$56,12456 claims
Aerie Pharmaceuticals, Inc.Rhopressa$24,833$21,59835 claims
AlconSimbrinza$777$9,98725 claims
NovartisTravatan Z$180$7,43813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →